Literature DB >> 16108036

A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis.

Javier Fernández1, Joan Monteagudo, Xavier Bargallo, Wladimiro Jiménez, Jaume Bosch, Vicente Arroyo, Miguel Navasa.   

Abstract

The administration of albumin improves circulatory function, prevents hepatorenal syndrome, and reduces hospital mortality in patients with cirrhosis and spontaneous bacterial peritonitis. This randomized unblinded pilot study compared the effect of albumin (10 patients) and the synthetic plasma expander hydroxyethyl starch 200/0.5 (10 patients) on the systemic hemodynamics of patients with spontaneous bacterial peritonitis. Baseline measurements were performed within 12 hours after diagnosis of infection. Patients then received 2 doses of the volume expander (1.5 g/kg body weight after baseline measurements and 1 g/kg body weight on day 3). Measurements were repeated after infection resolution. Treatment with albumin was associated with a significant increase in arterial pressure and a suppression of plasma renin activity, indicating an improvement in circulatory function. This occurred in the setting of a significant expansion of central blood volume (increase in cardiopulmonary pressures and atrial natriuretic factor) and an increase in systolic volume and systemic vascular resistance. In contrast, no significant changes were observed in these parameters in patients treated with hydroxyethyl starch. Von Willebrand-related antigen plasma levels significantly decreased in patients treated with albumin but not in those treated with hydroxyethyl starch. Serum nitrates and nitrites increased in patients treated with hydroxyethyl starch but not in those treated with albumin. These data suggest an effect of albumin on endothelial function. In conclusion, albumin but not hydroxyethyl starch improves systemic hemodynamics in patients with spontaneous bacterial peritonitis. This effect is due not only to volume expansion but also to an action on the peripheral arterial circulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16108036     DOI: 10.1002/hep.20829

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

Review 2.  Clinical use of albumin in hepatology.

Authors:  Matteo Garcovich; Maria Assunta Zocco; Antonio Gasbarrini
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

3.  Recommendations for the use of albumin and immunoglobulins.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossettias
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

4.  Spontaneous bacterial peritonitis: few additional points.

Authors:  Pankaj Jain
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

5.  5 Human Albumin.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 6.  Should albumin be used in all patients with spontaneous bacterial peritonitis?

Authors:  Neeraj Narula; Keith Tsoi; John K Marshall
Journal:  Can J Gastroenterol       Date:  2011-07       Impact factor: 3.522

7.  Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

Review 8.  Recent advances in cirrhotic cardiomyopathy.

Authors:  Dimitrios S Karagiannakis; George Papatheodoridis; Jiannis Vlachogiannakos
Journal:  Dig Dis Sci       Date:  2014-11-18       Impact factor: 3.199

Review 9.  Sepsis-induced acute kidney injury in patients with cirrhosis.

Authors:  Paolo Angeli; Marta Tonon; Chiara Pilutti; Filippo Morando; Salvatore Piano
Journal:  Hepatol Int       Date:  2015-07-04       Impact factor: 6.047

10.  Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference.

Authors:  Manuel Tufoni; Giacomo Zaccherini; Paolo Caraceni
Journal:  Ann Transl Med       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.